Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Enzon Pharmaceuticals Inc. (ENZN : OTC)

• Company Description    Enzon Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company's marketed drug products include PegIntron (R) for chronic hepatitis C; Sylatron (R) for Melanoma; Macugen (R) for neovascular age-related macular degeneration; CIMZIA (R) for Crohn's disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. Enzon Pharmaceuticals, Inc. is headquartered in Piscataway, New Jersey. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.10 Daily Weekly Monthly 20 Day Moving Average: 129,825 shares Shares Outstanding: 74.21 (millions) Market Capitalization: $7.24 (millions) Beta: 0.36 52 Week High: $0.24 52 Week Low: $0.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.30% 7.13% 12 Week -1.61% -17.25% Year To Date -37.54% -41.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20 Commerce Drive Suite 135 - Cranford,NJ 07016 USA ph: 732-980-4500 fax: 732-980-4585 investor@enzon.com http://www.enzon.com

• General Corporate Information    Officers Richard L. Feinstein - Chief Executive Officer; Chief Financial Officer a Randolph C. Read - Chairman Jordan Bleznick - Director Jaffray A. Firestone - Director Stephen T. Wills - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 293904108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 74.21 Most Recent Split Date: (:1) Beta: 0.36 Market Capitalization: $7.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.70 Price/Cash Flow: 9.30 Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -22.19 12/31/24 - 25.71 ROA 06/30/25 - - 03/31/25 - -1.28 12/31/24 - 1.65 Current Ratio 06/30/25 - - 03/31/25 - 82.17 12/31/24 - 28.10 Quick Ratio 06/30/25 - - 03/31/25 - 82.17 12/31/24 - 28.10 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - 1,150.00 12/31/24 - 4,326.92 Book Value 06/30/25 - - 03/31/25 - 0.03 12/31/24 - 0.04 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©